PMID- 29137041
OWN - NLM
STAT- MEDLINE
DCOM- 20171204
LR  - 20221005
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 96
IP  - 45
DP  - 2017 Nov
TI  - Efficacy of rituximab combined with CHOP for treating patients with diffuse large 
      B-cell lymphoma.
PG  - e8494
LID - 10.1097/MD.0000000000008494 [doi]
LID - e8494
AB  - BACKGROUND: This study aimed to evaluate the efficacy and safety of rituximab 
      combined with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) 
      for treating patients with diffuse large B-cell lymphoma (DLBCL). METHODS: A 
      total of 144 patients with DLBCL were randomly divided into intervention group 
      and control group, 72 patients in each group. The patients in the control group 
      received cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) 
      chemotherapy, while the participants in the intervention group received R-CHOP. 
      The primary endpoint was relapse-free survival (RFS) and the secondary endpoints 
      were overall survival rate (OSR) and adverse events (AEs). RESULTS: One hundred 
      thirty-four patients completed the study. The intervention with R-CHOP did not 
      show greater efficacy than CHOP in the estimated median follow-up time 
      (intervention group 33 months vs control group 29 months, P = .15). In addition, 
      no significant differences in the 5-year RFS (intervention group 81% vs placebo 
      group 76%, P = .28) or the 5-year OSR (intervention group 93% vs placebo group 
      91%, P = .53) were found between the 2 groups. The AEs were also similar between 
      the 2 groups. CONCLUSION: This study demonstrated that R-CHOP, when compared with 
      CHOP alone, could not improve the RFS and OS of patients with DLBCL. 
      Additionally, both groups had similar safety profiles.
FAU - Hu, Xin
AU  - Hu X
AD  - Department of Lymphoma Department of Chest Radiotherapy, Affiliated Tumor 
      Hospital of Xinjiang Medical University, Xinjiang, Urumqi, China.
FAU - Zeng, Min
AU  - Zeng M
FAU - Yang, Shun-E
AU  - Yang SE
FAU - Liang, Xiao
AU  - Liang X
FAU - Ding, Shan-Shan
AU  - Ding SS
FAU - Guo, Li
AU  - Guo L
FAU - Li, Shan
AU  - Li S
FAU - Wen, Shu-Juan
AU  - Wen SJ
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Antineoplastic Agents, Immunological)
RN  - 4F4X42SYQ6 (Rituximab)
RN  - 5J49Q6B70F (Vincristine)
RN  - 80168379AG (Doxorubicin)
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - VB0R961HZT (Prednisone)
RN  - CHOP protocol
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents, Immunological/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/administration & 
      dosage/*therapeutic use
MH  - Cyclophosphamide/administration & dosage/therapeutic use
MH  - Doxorubicin/administration & dosage/therapeutic use
MH  - Female
MH  - Humans
MH  - Lymphoma, Large B-Cell, Diffuse/*drug therapy/pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local
MH  - Prednisone/administration & dosage/therapeutic use
MH  - Rituximab/administration & dosage/adverse effects/*therapeutic use
MH  - Single-Blind Method
MH  - Survival Rate
MH  - Vincristine/administration & dosage/therapeutic use
PMC - PMC5690734
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2017/11/16 06:00
MHDA- 2017/12/05 06:00
PMCR- 2017/11/10
CRDT- 2017/11/16 06:00
PHST- 2017/11/16 06:00 [entrez]
PHST- 2017/11/16 06:00 [pubmed]
PHST- 2017/12/05 06:00 [medline]
PHST- 2017/11/10 00:00 [pmc-release]
AID - 00005792-201711100-00037 [pii]
AID - MD-D-17-05478 [pii]
AID - 10.1097/MD.0000000000008494 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2017 Nov;96(45):e8494. doi: 10.1097/MD.0000000000008494.